- Spectrum Pharmaceuticals (NASDAQ:SPPI) initiated with Buy rating and $26 (37% upside) price target by B. Riley FBR citing expected revenue of $125M - 130M through 2019 from oncology products and upside from Rolontis and poziotinib starting in 2020. Shares are up 3% premarket on light volume.
- Fate Therapeutics (NASDAQ:FATE) initiated with Overweight rating and $10 (138% upside) price target by Piper Jaffray.
- Pacira Pharmaceuticals (NASDAQ:PCRX) initiated with Neutral rating and $47 (7% upside) price target by JPMorgan (NYSE:JPM).
- Alexion Pharmaceuticals (NASDAQ:ALXN) upgraded to Outperform with a $150 (30% upside) price target by Robert Baird citing strong Siliris demand and label expansion. Shares are up 3% premarket on light volume.
- Teva Pharmaceutical Industries (NYSE:TEVA) upgraded to Outperform with a $21 (13% upside) price target by I.B.I.
- Now read: Wall Street Breakfast: All Eyes On The Tax Bill
Original article